BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation

Reuters
13 hours ago
BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation

March 6 (Reuters) - Ascentage Pharma Group International 6855.HK:

  • OLVEREMBATINIB GIVEN BREAKTHROUGH THERAPY DESIGNATION BY CENTER FOR DRUG EVALUATION OF CHINA NMPA

Further company coverage: 6855.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10